{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:13:46Z","timestamp":1787796826426,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"JSPS KAKENHI","award":["24390126"],"award-info":[{"award-number":["24390126"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s40780-015-0035-2","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T18:11:11Z","timestamp":1450807871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events"],"prefix":"10.1186","volume":"1","author":[{"given":"Mitsuhiro","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryogo","family":"Umetsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamato","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Sasaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutomi","family":"Kinosada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,22]]},"reference":[{"key":"35_CR1","first-page":"37","volume":"4","author":"LS Ruggiero","year":"2007","unstructured":"Ruggiero LS. Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin Cases Miner Bone Metab. 2007;4:37\u201342.","journal-title":"Clin Cases Miner Bone Metab."},{"key":"35_CR2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","volume":"35","author":"LS Ruggiero","year":"2009","unstructured":"Ruggiero LS, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of Jaw - 2009 Update. Aust Endod J. 2009;35:119\u201330.","journal-title":"Aust Endod J."},{"key":"35_CR3","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw \u22122014 update. J Oral Maxillofac Surg. 2014;72:1938\u201356.","journal-title":"J Oral Maxillofac Surg"},{"key":"35_CR4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/j.0022-0337.2008.72.8.tb04568.x","volume":"72","author":"A Mariotti","year":"2008","unstructured":"Mariotti A. Bisphosphonates and osteonecrosis of the jaws. J Dent Educ. 2008;72:919\u201329.","journal-title":"J Dent Educ."},{"key":"35_CR5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1248\/yakushi.13-00225","volume":"134","author":"R Umetsu","year":"2014","unstructured":"Umetsu R, Nishibata Y, Abe J, Suzuki Y, Hara H, Nagasawa H, et al. Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database. Yakugaku Zasshi. 2014;134:299\u2013304.","journal-title":"Yakugaku Zasshi."},{"key":"35_CR6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","volume":"35","author":"VR Cornelius","year":"2012","unstructured":"Cornelius VR, Sauzet O, Evans SJW. A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data. Drug Saf. 2012;35:599\u2013610.","journal-title":"Drug Saf."},{"key":"35_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3820\/jjpe.19.23","volume":"19","author":"M Yamada","year":"2014","unstructured":"Yamada M, Handa J. Comparison of the onset time profile among the interferon formulations in Adverse drug reaction of suicide- or diabetes related. Jpn J Pharmacoepidemiol. 2014;19:23\u201330.","journal-title":"Jpn J Pharmacoepidemiol."},{"key":"35_CR8","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36:995\u20131006.","journal-title":"Drug Saf."},{"key":"35_CR9","unstructured":"The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities. http:\/\/www.meddra.org\/ . Accessed 19 Aug 2015."},{"key":"35_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Puijenbroek Van","year":"2002","unstructured":"Van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"35_CR11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00774-010-0162-7","volume":"28","author":"T Yoneda","year":"2010","unstructured":"Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010;28:365\u201383.","journal-title":"J Bone Miner Metab."},{"key":"35_CR12","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","volume":"103","author":"KL Kavanagh","year":"2006","unstructured":"Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006;103:7829\u201334.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"35_CR13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/DHPS.S6285","volume":"2","author":"L Dalle Carbonare","year":"2010","unstructured":"Dalle Carbonare L, Zanatta M, Gasparetto A, Valenti MT. Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf. 2010;2:121\u201337.","journal-title":"Drug Healthc Patient Saf."},{"key":"35_CR14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","volume":"68","author":"JC Lo","year":"2010","unstructured":"Lo JC, O\u2019Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Predicting Risk of Osteonecrosis\u00a0of the\u00a0Jaw\u00a0with\u00a0Oral\u00a0Bisphosphonate\u00a0Exposure (PROBE) Investigators. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68:243\u201353.","journal-title":"J Oral Maxillofac Surg"},{"key":"35_CR15","unstructured":"United States Food and Drug Administration. Background document for meeting of advisory committee for reproductive health drugs and drug safety and risk management advisory committee. September 9, 2011. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/drugs\/DrugSafetyandRiskManagementAdvisoryCommittee\/UCM270958.pdf Accessed 15 Sep 2015."},{"key":"35_CR16","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/j.joms.2011.03.051","volume":"69","author":"M Urade","year":"2011","unstructured":"Urade M, Tanaka N, Furusawa K, Shimada J, Shibata T, Kirita T, et al. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg. 2011;69:e364\u201371.","journal-title":"J Oral Maxillofac Surg."},{"key":"35_CR17","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341\u20137.","journal-title":"Ann Oncol."},{"key":"35_CR18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/1759720X13485829","volume":"5","author":"I Ruza","year":"2013","unstructured":"Ruza I, Mirfakhraee S, Orwoll E, Gruntmanis U. Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions. Ther Adv Musculoskelet Dis. 2013;5:182\u201398.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"35_CR19","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1248\/bpb.b14-00191","volume":"38","author":"Y Suzuki","year":"2015","unstructured":"Suzuki Y, Suzuki H, Umetsu R, Uranishi H, Abe J, Nishibata Y, et al. Analysis of the Interaction between clopidogrel, aspirin, and proton pump inhibitors using the FDA Adverse Event Reporting System Database. Biol Pharm Bull. 2015;38:680\u20136.","journal-title":"Biol Pharm Bull."},{"key":"35_CR20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40780-015-0015-6","volume":"1","author":"Y Kato","year":"2015","unstructured":"Kato Y, Umetsu R, Abe J, Ueda N, Nakayama Y, Kinosada Y, et al. Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports. J Pharm Health Care Sci. 2015;1:15.","journal-title":"J Pharm Health Care Sci."}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-015-0035-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T04:08:41Z","timestamp":1599970121000},"score":1,"resource":{"primary":{"URL":"http:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-015-0035-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1186\/s40780-015-0035-2","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"34"}}